These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21563232)

  • 1. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
    Huang J; Zhang L; Greshock J; Colligon TA; Wang Y; Ward R; Katsaros D; Lassus H; Butzow R; Godwin AK; Testa JR; Nathanson KL; Gimotty PA; Coukos G; Weber BL; Degenhardt Y
    Genes Chromosomes Cancer; 2011 Aug; 50(8):606-18. PubMed ID: 21563232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
    Cui W; Cai Y; Wang W; Liu Z; Wei P; Bi R; Chen W; Sun M; Zhou X
    J Transl Med; 2014 Jan; 12():10. PubMed ID: 24418330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
    Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
    Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma.
    De Marco C; Rinaldo N; Bruni P; Malzoni C; Zullo F; Fabiani F; Losito S; Scrima M; Marino FZ; Franco R; Quintiero A; Agosti V; Viglietto G
    PLoS One; 2013; 8(2):e55362. PubMed ID: 23408974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Lee S; Choi EJ; Jin C; Kim DH
    Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
    Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
    Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.
    Dobbin ZC; Landen CN
    Int J Mol Sci; 2013 Apr; 14(4):8213-27. PubMed ID: 23591839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
    Cheng JC; Auersperg N; Leung PC
    Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN-deficient cancers depend on PIK3CB.
    Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway.
    Yang Y; Zhang J; Zhu Y; Zhang Z; Sun H; Feng Y
    Int J Gynecol Cancer; 2014 Nov; 24(9):1564-74. PubMed ID: 25340291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
    Carden CP; Stewart A; Thavasu P; Kipps E; Pope L; Crespo M; Miranda S; Attard G; Garrett MD; Clarke PA; Workman P; de Bono JS; Gore M; Kaye SB; Banerji U
    Mol Cancer Ther; 2012 Jul; 11(7):1609-17. PubMed ID: 22556379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M
    Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
    Bellmunt J; Werner L; Leow JJ; Mullane SA; Fay AP; Riester M; Van Hummelen P; Taplin ME; Choueiri TK; Van Allen E; Rosenberg J
    PLoS One; 2015; 10(6):e0124711. PubMed ID: 26039708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
    Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
    Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
    Fan Y; Wang L; Han X; Liu X; Ma H
    Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
    Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.